Skip to main content

Table 2 The clinical and biochemical characteristics in OHT patients and non-OHT patients

From: Glucocorticoid therapy reduces ocular hypertension in active moderate-severe thyroid-associated orbitopathy

 

Non-OHT patients

(n = 30)

OHT patients

(n = 38)

P

Age, years

49.76 ± 14.57

50.13 ± 13.44

0.94*

Male/Female,n

14/16

25/13

0.14#

Current smokers,n

19

21

0.63#

The kind of thyroid disease (GD/HT,n)

28/2

36/2

1.0#

Duration of thyroid disease,month

13.73 ± 24.11

24.89 ± 48.97

0.26*

Duration of eye symptoms,month

6.64 ± 8.88

7.08 ± 8.34

0.63*

 FT3(pg/ml)

3.61 ± 0.77

3.62 ± 0.5

0.98*

 FT4(ng/dl)

0.88 ± 0.23

0.93 ± 0.13

0.07*

 TSH(uIU/ml)

1.19 ± 1.73

1.04 ± 1.83

0.99*

 TRAb(IU/l)

16.61 ± 12.34

11.88 ± 8.1

0.10*

 TgAb(IU/l)

127.68 ± 340.04

80.56 ± 221.78

0.40*

 TpoAb(IU/l)

201.76 ± 339.58

115.82 ± 220.02

0.56*

  1. Data represented as mean ± SD
  2. HT Hashimoto disease, GD Grave’s disease, OHT Ocular hypertension, n number
  3. #P:χ2 test; *P:Mann–Whitney U test
  4. P < 0.05 were considered statistically significant
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us